Keros Therapeutics (KROS) Officer Reports RSUs and Multiple Option Grants
Rhea-AI Filing Summary
Esther Cho, SVP and General Counsel of Keros Therapeutics, Inc. (KROS), reported initial beneficial ownership on Form 3 for an event dated 08/06/2025. She directly holds 44,000 shares (RSUs) and beneficially owns employee stock options exercisable into 165,968 common shares across five option grants with exercise prices ranging from $29.02 to $70.93.
Positive
- Disclosure completeness: The Form 3 provides detailed reporting of both non-derivative RSUs and multiple derivative option grants.
- Transparent vesting terms: RSU and option vesting schedules and exercise prices are clearly stated, enabling assessment of timing and potential exercise economics.
Negative
- Potential dilution: Derivative securities cover 165,968 common shares, which could dilute existing shareholders if exercised.
Insights
TL;DR: Routine insider disclosure shows executive equity compensation concentrated in stock options and RSUs, standard for senior management.
The filing documents the initial beneficial ownership by the company’s SVP and General Counsel, combining 44,000 vested/vesting RSUs and 165,968 option-equivalent shares across grants with exercise prices from $29.02 to $70.93. The options include immediate exercisable tranches and staggered vesting schedules, indicating ongoing retention-focused compensation rather than a one-time transaction. This disclosure is procedural and provides transparency on potential future dilution.
TL;DR: Governance standard filing; documents officer’s equity holdings and vesting terms to satisfy Section 16 reporting obligations.
The Form 3 fulfills Section 16(a) initial reporting requirements for a named officer. It specifies vesting schedules for RSUs and multiple option grants, with explicit vesting milestones through 2034 and some options immediately exercisable. These details allow stakeholders to assess alignment incentives and the timeline for when equity may become transferable. The disclosure itself is routine and non-eventful.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person continuing to provide service through each such date. Immediately exercisable. One-fourth (1/4th) of the shares subject to the option vested on January 19, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. One-fourth (1/4th) of the shares subject to the option vested on February 16, 2024, and one-twelfth (1/12th) of the remaining shares subject to the option vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. One-fourth (1/4th) of the shares subject to the option vested on February 13, 2025, and one-twelfth (1/12th) of the remaining shares subject to the option vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
